The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy

References

• Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8:671-82; PMID:18650841; http://dx.doi.org/10.1038/nrc2399
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8:714-24; PMID:19143056; http://dx.doi.org/10.1038/nrc2401
   PubMed Web of Science ®Google Scholar
• Miccadei S, Provenzano C, Mojzisek M, Natali PG, Civitareale D. Retinoblastoma protein acts as Pax 8 transcriptional coactivator. Oncogene 2005; 24:6993-7001; PMID:16007137; http://dx.doi.org/10.1038/sj.onc.1208861
   PubMed Web of Science ®Google Scholar
• Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 2001; 8:303-16; PMID:11545733; http://dx.doi.org/10.1016/S1097-2765(01)00327-6
   PubMed Web of Science ®Google Scholar
• Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 1997; 6:437-47; PMID:9133423; http://dx.doi.org/10.1016/S1074-7613(00)80287-3
   PubMed Web of Science ®Google Scholar
• Kueh HY, Champhekar A, Nutt SL, Elowitz MB, Rothenberg EV. Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. Science 2013; 341:670-3; PMID:23868921; http://dx.doi.org/10.1126/science.1240831
   PubMed Web of Science ®Google Scholar
• Kadri Z, Shimizu R, Ohneda O, Maouche-Chretien L, Gisselbrecht S, Yamamoto M, Romeo PH, Leboulch P, Chretien S. Direct binding of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis. PLoS Biol 2009; 7:e1000123; PMID:19513100; http://dx.doi.org/10.1371/journal.pbio.1000123
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Choe KS, Matushansky I, Murray S, Stopka T, Skoultchi AI. PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation. Mol Cell Biol 2003; 23:7460-74; PMID:14559995; http://dx.doi.org/10.1128/MCB.23.21.7460-7474.2003
   PubMed Web of Science ®Google Scholar
• Charles A, Tang X, Crouch E, Brody JS, Xiao ZX. Retinoblastoma protein complexes with C/EBP proteins and activates C/EBP-mediated transcription. J Cell Biochem 2001; 83:414-25; PMID:11596110; http://dx.doi.org/10.1002/jcb.1239
   PubMed Web of Science ®Google Scholar
• Johnson-Pais T, Degnin C, Thayer MJ. pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc Natl Acad Sci U S A 2001; 98:2211-6; PMID:11226218; http://dx.doi.org/10.1073/pnas.051415898
   PubMed Web of Science ®Google Scholar
• Jamal R, Gale RE, Shaun N, Thomas B, Wheatley K, Linch DC. The retinoblastoma gene (rb1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome. Br J Haematol 1996; 94:342-51; PMID:8759895; http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1804.x
   PubMed Web of Science ®Google Scholar
• Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007; 129:1081-95; PMID:17574022; http://dx.doi.org/10.1016/j.cell.2007.03.055
   PubMed Web of Science ®Google Scholar
• Viatour P, Somervaille TC, Venkatasubrahmanyam S, Kogan S, McLaughlin ME, Weissman IL, Butte AJ, Passegue E, Sage J. Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell 2008; 3:416-28; PMID:18940733; http://dx.doi.org/10.1016/j.stem.2008.07.009
   PubMed Web of Science ®Google Scholar
• Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45:242-52; PMID:23334668; http://dx.doi.org/10.1038/ng.2532
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319:47-65; PMID:24965257; http://dx.doi.org/10.1111/nyas.12469
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012; 22:275-81; PMID:22313874; http://dx.doi.org/10.1016/j.semcancer.2012.01.011
   PubMed Web of Science ®Google Scholar
• Dai J, El Gazzar M, Li GY, Moorman JP, Yao ZQ. Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity. J Innate Immun 2014; PMID:25401944
   PubMed Web of Science ®Google Scholar
• Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013; 14:211-20; PMID:23354483; http://dx.doi.org/10.1038/ni.2526
   PubMed Web of Science ®Google Scholar
• Markey MP, Bergseid J, Bosco EE, Stengel K, Xu H, Mayhew CN, Schwemberger SJ, Braden WA, Jiang Y, Babcock GF, et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene 2007; 26:6307-18; PMID:17452985; http://dx.doi.org/10.1038/sj.onc.1210450
   PubMed Web of Science ®Google Scholar
• Hutcheson J, Bourgo RJ, Balaji U, Ertel A, Witkiewicz AK, Knudsen ES. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance to hepatocellular carcinoma. Hepatology 2014; PMID:24824777
   PubMed Web of Science ®Google Scholar
• Longworth MS, Walker JA, Anderssen E, Moon NS, Gladden A, Heck MM, Ramaswamy S, Dyson NJ. A shared role for RBF1 and dCAP-D3 in the regulation of transcription with consequences for innate immunity. PLoS Genet 2012; 8:e1002618; PMID:22496667; http://dx.doi.org/10.1371/journal.pgen.1002618
   PubMedGoogle Scholar
• Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer science 2004; 95:697-703; PMID:15471553; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03248.x
   PubMed Web of Science ®Google Scholar
• Pulendran B, Artis D. New paradigms in type 2 immunity. Science 2012; 337:431-5; PMID:22837519; http://dx.doi.org/10.1126/science.1221064
   PubMed Web of Science ®Google Scholar
• Dalessandri T, Strid J. Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer. Front Immunol 2014; 5:347; PMID:25101088; http://dx.doi.org/10.3389/fimmu.2014.00347
   PubMed Web of Science ®Google Scholar
• Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G, Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996; 88:2219-27; PMID:8822942
   PubMed Web of Science ®Google Scholar
• Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 1991; 88:7605-9; PMID:1652755; http://dx.doi.org/10.1073/pnas.88.17.7605
   PubMed Web of Science ®Google Scholar
• Zhu YM, Bradbury DA, Keith FJ, Russell N. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia 1994; 8:1982-8; PMID:7967742
   PubMed Web of Science ®Google Scholar
• Zhu X, Pattenden S, Bremner R. pRB is required for interferon-gamma-induction of the MHC class II abeta gene. Oncogene 1999; 18:4940-7; PMID:10490828; http://dx.doi.org/10.1038/sj.onc.1202876
   PubMed Web of Science ®Google Scholar
• Lu Y, Tschickardt ME, Schmidt BJ, Blanck G. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol 1997; 75:325-32; PMID:9315472; http://dx.doi.org/10.1038/icb.1997.50
   PubMed Web of Science ®Google Scholar
• Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J Immunol 1996; 156:2495-502; PMID:8786310
   PubMed Web of Science ®Google Scholar
• Lu Y, Ussery GD, Jacim M, Tschickardt M, Boss JM, Blanck G. Retinoblastoma protein regulation of surface CD74 (invariant chain) expression in breast carcinoma cells. Mol Immunol 1994; 31:1365-8; PMID:7997248; http://dx.doi.org/10.1016/0161-5890(94)90055-8
   PubMed Web of Science ®Google Scholar
• Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blanck G. Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene 1994; 9:1015-9; PMID:8134104
   PubMed Web of Science ®Google Scholar
• Osborne A, Tschickardt M, Blanck G. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res 1997; 25:5095-102; PMID:9396821; http://dx.doi.org/10.1093/nar/25.24.5095
   PubMed Web of Science ®Google Scholar
• Osborne AR, Zhang H, Blanck G. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line. Mol Immunol 2006; 43:710-6; PMID:16360016; http://dx.doi.org/10.1016/j.molimm.2005.03.013
   PubMed Web of Science ®Google Scholar
• Osborne A, Zhang H, Yang WM, Seto E, Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol 2001; 21:6495-506; PMID:11533238; http://dx.doi.org/10.1128/MCB.21.19.6495-6506.2001
   PubMed Web of Science ®Google Scholar
• Zhang H, Shepherd AT, Eason DD, Wei S, Diaz JI, Djeu JY, Wu GD, Blanck G. Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Cell Growth Differ 1999; 10:457-65; PMID:10437913
   PubMedGoogle Scholar
• Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem 2004; 279:28911-9; PMID:15105429; http://dx.doi.org/10.1074/jbc.M403118200
   PubMed Web of Science ®Google Scholar
• Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G. Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. Gene 2013; 512:403-7; PMID:23041127; http://dx.doi.org/10.1016/j.gene.2012.09.092
   PubMed Web of Science ®Google Scholar
• Xu L, Niesen MI, Blanck G. Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Mol Immunol 2009; 46:569-75; PMID:18952290; http://dx.doi.org/10.1016/j.molimm.2008.07.035
   PubMed Web of Science ®Google Scholar
• Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 1990; 64:723-30; PMID:2153238
   PubMed Web of Science ®Google Scholar
• Zwerschke W, Jansen-Durr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv Cancer Res 2000; 78:1-29; PMID:10547667; http://dx.doi.org/10.1016/S0065-230X(08)61022-2
   PubMed Web of Science ®Google Scholar
• Croul S, Otte J, Khalili K. Brain tumors and polyomaviruses. J Neurovirol 2003; 9:173-82; PMID:12707848; http://dx.doi.org/10.1080/13550280390194055
   PubMed Web of Science ®Google Scholar
• Helt AM, Galloway DA. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003; 24:159-69; PMID:12584163; http://dx.doi.org/10.1093/carcin/24.2.159
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol 2014; 184:574-83; PMID:24388934; http://dx.doi.org/10.1016/j.ajpath.2013.10.028
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511; PMID:15229469; http://dx.doi.org/10.1038/nri1391
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9:57-63; PMID:19052556; http://dx.doi.org/10.1038/nrc2541
   PubMed Web of Science ®Google Scholar
• Taura M, Suico MA, Koyama K, Komatsu K, Miyakita R, Matsumoto C, Kudo E, Kariya R, Goto H, Kitajima S, et al. Rb/E2F1 regulates the innate immune receptor Toll-like receptor 3 in epithelial cells. Mol Cell Biol 2012; 32:1581-90; PMID:22310660; http://dx.doi.org/10.1128/MCB.06454-11
   PubMed Web of Science ®Google Scholar
• Garcia MA, Gallego P, Campagna M, Gonzalez-Santamaria J, Martinez G, Marcos-Villar L, Vidal A, Esteban M, Rivas C. Activation of NF-kB pathway by virus infection requires Rb expression. PLoS One 2009; 4:e6422; PMID:19649275; http://dx.doi.org/10.1371/journal.pone.0006422
   PubMed Web of Science ®Google Scholar
• DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988; 54:275-83; PMID:2839300; http://dx.doi.org/10.1016/0092-8674(88)90559-4
   PubMed Web of Science ®Google Scholar
• Harris KF, Christensen JB, Imperiale MJ. BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. J Virol 1996; 70:2378-86; PMID:8642665
   PubMed Web of Science ®Google Scholar
• Krynska B, Gordon J, Otte J, Franks R, Knobler R, DeLuca A, Giordano A, Khalili K. Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein. J Cell Biochem 1997; 67:223-30; PMID:9328827; http://dx.doi.org/10.1002/(SICI)1097-4644(19971101)67:2%3c223::AID-JCB7%3e3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Shahzad N, Shuda M, Gheit T, Kwun HJ, Cornet I, Saidj D, Zannetti C, Hasan U, Chang Y, Moore PS, et al. The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol 2013; 87:13009-19; PMID:24067965; http://dx.doi.org/10.1128/JVI.01786-13
   PubMed Web of Science ®Google Scholar
• Weihua X, Ramanujam S, Lindner DJ, Kudaravalli RD, Freund R, Kalvakolanu DV. The polyoma virus T antigen interferes with interferon-inducible gene expression. Proc Natl Acad Sci U S A 1998; 95:1085-90; PMID:9448289; http://dx.doi.org/10.1073/pnas.95.3.1085
   PubMed Web of Science ®Google Scholar
• Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000; 1:70-6; PMID:10881178; http://dx.doi.org/10.1038/76940
   PubMed Web of Science ®Google Scholar
• Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncol Lett 2011; 2:583-9; PMID:22848232
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96:41-101; PMID:17981204; http://dx.doi.org/10.1016/S0065-2776(07)96002-2
   PubMed Web of Science ®Google Scholar
• Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275:6764-9; PMID:10702232; http://dx.doi.org/10.1074/jbc.275.10.6764
   PubMed Web of Science ®Google Scholar
• Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J General Virol 2013; 94:2504-14; PMID:23956301; http://dx.doi.org/10.1099/vir.0.054486-0
   PubMed Web of Science ®Google Scholar
• Cook JL, Walker TA, Worthen GS, Radke JR. Role of the E1A Rb-binding domain in repression of the NF-kappa B-dependent defense against tumor necrosis factor-alpha. Proc Natl Acad Sci U S A 2002; 99:9966-71; PMID:12119420; http://dx.doi.org/10.1073/pnas.162082999
   PubMed Web of Science ®Google Scholar
• Fera D, Marmorstein R. Different regions of the HPV-E7 and Ad-E1A viral oncoproteins bind competitively but through distinct mechanisms to the CH1 transactivation domain of p300. Biochemistry 2012; 51:9524-34; PMID:23121466; http://dx.doi.org/10.1021/bi3011863
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 2010; 16:1094-9; PMID:20145169; http://dx.doi.org/10.1158/1078-0432.CCR-09-0787
   PubMed Web of Science ®Google Scholar
• Elfstrom KM, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L. Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review. Curr Opin Oncol 2014; 26:120-9; PMID:24248011; http://dx.doi.org/10.1097/CCO.0000000000000034
   PubMed Web of Science ®Google Scholar
• Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice. J Virol Methods 2014; 206:12-8; PMID:24880067; http://dx.doi.org/10.1016/j.jviromet.2014.05.013
   PubMed Web of Science ®Google Scholar
• Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, Teh M. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007; 109:1097-105; PMID:17311305; http://dx.doi.org/10.1002/cncr.22503
   PubMed Web of Science ®Google Scholar
• Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP, Carrieri G. Retinoblastoma protein expression predicts response to bacillus Calmette-Guerin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 2010; 28:285-9; PMID:18976938; http://dx.doi.org/10.1016/j.urolonc.2008.08.003
   PubMed Web of Science ®Google Scholar
• Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014; 65:185-202; PMID:24188664; http://dx.doi.org/10.1146/annurev-med-092012-112807
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004; 64:1867-74; PMID:14996751; http://dx.doi.org/10.1158/0008-5472.CAN-03-2634
   PubMed Web of Science ®Google Scholar
• Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 2007; 67:4499-506; PMID:17483366; http://dx.doi.org/10.1158/0008-5472.CAN-06-3770
   PubMed Web of Science ®Google Scholar
• Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol 2008; 57:389-98; PMID:17724589; http://dx.doi.org/10.1007/s00262-007-0381-5
   PubMedGoogle Scholar
• Srivastava MK, Bosch JJ, Wilson AL, Edelman MJ, Ostrand-Rosenberg S. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int J Cancer 2010; 127:2612-21; PMID:20473949; http://dx.doi.org/10.1002/ijc.25462
   PubMed Web of Science ®Google Scholar